Key result
Reperfusion cuts short-term mortality ~53% vs non-reperfusion in patients ≥75 with AMI and cardiogenic shock.
Why the study?
Older adults with AMI complicated by cardiogenic shock face higher risks of adverse outcomes and complications, but remain under-represented in clinical trials, leaving the efficacy of reperfusion therapy unclear.
Does reperfusion therapy reduce short-term mortality in patients aged ≥75 years with acute myocardial infarction and cardiogenic shock?
Meta-Analysis (n=4,583)
Does reperfusion therapy reduce short-term mortality in patients aged ≥75 years with acute myocardial infarction and cardiogenic shock?
In older adults (≥75 years) with acute myocardial infarction complicated by cardiogenic shock, reperfusion therapy is associated with a significant reduction in short-term mortality compared to non-reperfusion therapy.
Answers are grounded in this paper and cite their sources.
Supports reperfusion for short-term survival in elderly AMI-shock patients; extends meta-analytic evidence to this high-risk group.
BACKGROUND Reperfusion therapy is the cornerstone of treatment for acute myocardial infarction (AMI) complicated by cardiogenic shock (CS). However, older adults with AMI and CS face higher risks of adverse outcomes and procedure-related complications. Since this population is under-represented in clinical trials, the efficacy of reperfusion therapy remains unclear. We performed a meta-analysis to evaluate the impact of reperfusion therapy on mortality in older adults with AMI and CS. METHODS We searched PUBMED and EMBASE through 4/1/2025 for studies comparing reperfusion therapy with percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) and non-reperfusion therapy for AMI and CS in patients aged ≥75 years. We included prospective and retrospective observational trials reporting clinical outcomes. The primary outcome was set as short-term mortality, and the secondary outcome was long-term mortality. We performed subgroup analysis of the primary outcome for patients with ST-segment elevation myocardial infarction and those without. RESULTS Our search identified 14 eligible studies in a total of 4583 patients. Reperfusion therapy was associated with significantly reduced short-term mortality, compared with non-reperfusion therapy with high heterogeneity (odds ratio (OR): 0.47; 95% confidence interval (CI): 0.30-0.73, I2 = 76.8%). There was no significant difference in long-term all-cause mortality between reperfusion and non-reperfusion therapy (OR: 0.66; 95% CI: 0.34-1.26, I2 = 79.7%). The subgroup analyses were largely consistent with the main findings. CONCLUSIONS Reperfusion therapy was associated with reduced short-term mortality, compared to non-reperfusion therapy for older patients with AMI and CS. Reperfusion therapy showed a tendency towards reduced long-term mortality.
No takes yet. Share an insight, caveat, or question.
Kiyohara et al. (2026) conducted a meta-analysis in Acute myocardial infarction complicated by cardiogenic shock (n=4,583). Reperfusion therapy (PCI or CABG) vs. Non-reperfusion therapy was evaluated on Short-term mortality (OR 0.47, 95% CI 0.30-0.73). Reperfusion therapy reduced short-term mortality compared to non-reperfusion therapy in patients aged ≥75 years with AMI and cardiogenic shock.
Synapse has enriched 10 related papers. Consider them for comparative context: